WHO WE ARE

We are a health economics and outcomes research Consultancy Company

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

WHO WE ARE

We are a health economics and outcomes research Consultancy Company

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

WHO WE ARE

We are a health economics and outcomes research Consultancy Company

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

We help you to identify a clear pathway for reimbursement and adoption of your product across major global healthcare markets.

previous arrow
next arrow
Slider

WHAT WE DO

We help you to develop your value story and pricing and reimbursement strategy

Card image cap
Card image cap
Card image cap
Card image cap
WE SUPPORT

YOUR EARLY MARKET ACCESS STRATEGY

which includes analysis of market access landscape, early product value assessment, early payer engagement, payer advisory boards, value dossiers, payer communication tools.

WE SUPPORT

YOUR NATIONAL MARKET ACCESS STRATEGY

which includes HTA and reimbursement submissions, systematic and rapid literature reviews, cost-consequence and cost effectiveness modelling, budget impact modelling, publications, conference presentation and training and workshops.

WE SUPPORT

YOUR LOCAL MARKET ACCESS STRATEGY

which includes developing bespoke business cases allowing you to engage with key hospital decision makers and become a trusted solution provider through your technology.

WE SUPPORT

YOUR GLOBAL MARKET ACCESS STRATEGY

Which includes the process of conducting country-specific adaptations of global health economic models and determining applicable regulations and managing product compliance to those regulations.

OUR SERVICES

We help you to develop your value story and pricing and reimbursement strategy

MARKET OPPORTUNITIES

Engage with the world's leading and largest healthcare system

£11.5M

SPENT ON CLINICAL RESEARCH EVERY DAY

£25BN

SPENT ON GOODS AND SERVICES EVERY YEAR

200+

CLINICAL COMMISSIONING GROUPS (CCGS)

61M+

POTENTIAL PATIENTS

TEAM MEMBERS

A blend of experience from consultancy, industry and academia

A rad wolf
Atefeh was an Evidence Synthesis Analyst at NIHR Innovation Observatory. She was also a member of the Evidence Synthesis and Health Economics Teams in the Institute of Health & Society. She has a strong background in health economics and Evidence Synthesis. She has published several Cochrane systematic reviews.
Atefeh Mashayekhi
Head of Evidence Synthesis Team
A rad wolf
Mehdi holds a Ph.D. in Health Economics and has over 12 years of experiences in academia and industry. Mehdi has built over 60 economic evaluation models from scratch for different diseases (Cancer, diabetes, cardiovascular diseases, Ophthalmology, ...) and has over 80 publications in high impact journals. He has a strong commercial sense and in-depth knowledge of modeling. His work includes early economic modeling, cost-effectiveness, and budget impact models, validation of existing models and production of affiliate models fully adaptable for country-specific inputs.
Dr Mehdi Javanbakht
Chief Executive Officer (CEO)
A rad wolf
Maziar is a Medical Doctor with post-graduate studies in health metric and evaluation. He has been a consultant for several international organizations, governments, and companies. Maziar has contributed to publishing more than 180 papers in peer-reviewed journals.
Professor Maziar Moradi-Lakeh
Head of Clinical Research Team
A rad wolf
Mohsen holds a PhD in health economics with several years of experience in academia and industry. He has built several economic evaluation models in different diseases area.
Dr Mohsen Yaghoubi
Senior Health Economics Scientist

OUR NETWORK

Building successful relationships

CLIENT TESTIMONIALS

Optimax Access team are very professional, they were really helpful and the economic model that they built for our value proposition story was really great


Chief Medical Officer

Scott

We enjoyed working with Optimax Access team, they have a very deep understanding of Market Access strategies, look forward to working with them again


Market Access Manager

Dan